Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloablative therapy for primary resistant multiple myeloma

R Alexanian1, M A Dimopoulos, K B Delasalle

  • 1University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Stem Cells (Dayton, Ohio)
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.

Seminars in hematology·2023
Same author

Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management.

Seminars in hematology·2023
Same author

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Ex vivo-expanded human CD19<sup>+</sup>TIM-1<sup>+</sup> regulatory B cells suppress immune responses in vivo and are dependent upon the TIM-1/STAT3 axis.

Nature communications·2022
Same journal

Correction to: Mitochondrial Transfer from Mesenchymal Stem Cells to Macrophages Restricts Inflammation and Alleviates Kidney Injury in Diabetic Nephropathy Mice via PGC-1α Activation.

Stem cells (Dayton, Ohio)·2026
Same journal

Correction to: Critical role of the potential O-linked glycosylation sites of CXCR4 in cell migration and bone marrow homing of hematopoietic stem progenitor cells.

Stem cells (Dayton, Ohio)·2026
Same journal

Brent A. Reynolds, pioneer of adult neural stem cell biology.

Stem cells (Dayton, Ohio)·2026
Same journal

CircVapa promotes the abnormal differentiation of small intestinal epithelial stem cells in diabetic state.

Stem cells (Dayton, Ohio)·2026
Same journal

Transforming Growth Factor beta-2 (TGFβ2) Drives Trabecular Meshwork Progenitor Cell Differentiation Through SMAD2/3 Signalling.

Stem cells (Dayton, Ohio)·2026
Same journal

Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2/SOX2 in breast cancer cells.

Stem cells (Dayton, Ohio)·2026
See all related articles

High-dose chemotherapy with autologous stem cell transplant effectively treats resistant multiple myeloma, quadrupling survival in patients with significant tumor reduction. Early intervention is crucial for optimal outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Multiple myeloma is a hematologic malignancy resistant to standard therapies.
  • Vincristine-doxorubicin with high-dose dexamethasone (VAD) is a common treatment regimen.
  • Advanced or resistant multiple myeloma poses significant treatment challenges.

Purpose of the Study:

  • To evaluate the efficacy of myeloablative therapy with autologous stem cell transplantation.
  • To assess treatment outcomes in patients with multiple myeloma resistant to VAD or similar regimens.

Main Methods:

  • Myeloablative therapy followed by autologous bone marrow or blood stem cell transplantation.
  • Treatment administered to 41 patients with advanced, VAD-resistant multiple myeloma.
  • Tumor burden and survival compared to a matched control group.

Related Experiment Videos

Main Results:

  • Over 75% myeloma cell mass reduction in 56% of patients with high/intermediate tumor burden.
  • Quadrupled survival time observed in treated patients compared to controls.
  • Later treatment initiation led to lower response rates and shorter remissions.

Conclusions:

  • Myeloablative regimens with autologous stem cells offer a valuable treatment for advanced, resistant multiple myeloma.
  • Early administration of this therapy maximizes remission chances.
  • Optimizing stem cell collection and minimizing procedural complications are key for success.